Phase I Results – Nerofe’s Triple Actionadmin2015-11-03T19:41:57+00:00
Nerofe is acting on heavily treated patients
Tumor growth is inhibited in patients under Nerofe treatment
Tumor size after Nerofe treatment – CT
Nerofe administration was associated with orders of magnitude decreases in plasma levels of Angiopoeitin-1, PDGF AA, TGF-β1 and VEGF in all patients in cohorts 3 and 4. This effect wasn’t observed to the same extent on the lower treatment dosage, suggesting a Nerofe dosage dependent induction of anti-angiogenesis.
Anti-proliferative effect
In 3 patients with elevated serum EGF levels, levels decreased to normal values (Remaining patients entered trial with normal EGF levels)
In Cohorts 3 and 4 major pro-inflammatory cytokines serum levels increased significantly, an effect not seen in the lower treatment dosages, suggesting a Nerofe dosage dependent induction of immune system response to the tumor.
Selective biomarker for efficacy
Patients whose tumor was positively stained for T1/ST2 receptor stayed in trial with SD significantly longer than patients who had a tumor that was negatively stained.
